{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:53:06Z","timestamp":1781653986355,"version":"3.54.5"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":113,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metab"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The dimeric AP-1 transcription factor has been described as a regulator of bone metabolism, but also of adipocyte biology. More specifically, its family members adopt specific functions in the regulation of adipocyte differentiation and adipose tissue hypoxia, but also in controlling lipolysis, energy expenditure and insulin sensitivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we analyzed the role of the AP-1 family member Fos, whose ubiquitous over-expression in transgenic mice has been described to cause osteosarcoma formation, on adipose tissue, glucose and lipid metabolism. More specifically, we analyzed the metabolic phenotype of the respective mouse model by histological analyses, monitoring gene expression, determination of serum parameters and ex vivo adipogenesis assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We show that\n                      <jats:italic>Fos<\/jats:italic>\n                      Tg mice additionally display an age-dependent loss of white adipose tissue, which is associated with reduced adipocyte size. Quantitative real-time PCR analyses of white adipose tissue as well as in vitro studies using adipocyte-derived stromal cells excluded a cell-autonomous defect in adipocyte differentiation. However,\n                      <jats:italic>Fos<\/jats:italic>\n                      Tg mice displayed low circulating glucose levels along with increased glucose tolerance and insulin sensitivity. By proteomic analysis we identified elevated serum levels of fibroblast growth factor 21 (Fgf21) in\n                      <jats:italic>Fos<\/jats:italic>\n                      Tg mice which could explain the observed reduced hepatic lipogenesis and white adipose tissue mass. Most importantly, we demonstrated that this metabolic phenotype is dependent on osteosarcoma formation by crossing the\n                      <jats:italic>Fos<\/jats:italic>\n                      Tg mice with mice deficient for\n                      <jats:italic>Rsk2<\/jats:italic>\n                      , a kinase necessary for tumor growth. Moreover, we could show a direct correlation between tumor burden and Fgf21 serum levels in our mouse model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In summary, our data identify Fgf21 as a potential regulator of glucose and lipid metabolism in\n                      <jats:italic>Fos<\/jats:italic>\n                      transgenic osteosarcoma-bearing mice, thereby supporting its essential function in the regulation of the metabolic phenotype associated with cancer cachexia.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40170-025-00417-y","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:04:33Z","timestamp":1770138273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fos-induced osteosarcoma growth causes a cachexia-like phenotype in mice and correlates with high Fgf21 serum levels"],"prefix":"10.1186","volume":"14","author":[{"given":"Julia","family":"Luther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Carreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Baldauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Koehne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Amling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"11","key":"417_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nrc1209","volume":"3","author":"R Eferl","year":"2003","unstructured":"Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3(11):859\u201368.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"417_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/ar2338","volume":"10","author":"R Zenz","year":"2008","unstructured":"Zenz R, Eferl R, Scheinecker C, Redlich K, Smolen J, Schonthaler HB, et al. Activator protein 1 (Fos\/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther. 2008;10(1):201.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"417_CR3","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/79676","volume":"6","author":"W Jochum","year":"2000","unstructured":"Jochum W, David JP, Elliott C, Wutz A, Plenk H Jr., Matsuo K, et al. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med. 2000;6(9):980\u20134.","journal-title":"Nat Med"},{"issue":"9","key":"417_CR4","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/79683","volume":"6","author":"G Sabatakos","year":"2000","unstructured":"Sabatakos G, Sims NA, Chen J, Aoki K, Kelz MB, Amling M, et al. Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med. 2000;6(9):985\u201390.","journal-title":"Nat Med"},{"issue":"6","key":"417_CR5","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1083\/jcb.201002111","volume":"190","author":"A Bozec","year":"2010","unstructured":"Bozec A, Bakiri L, Jimenez M, Schinke T, Amling M, Wagner EF. Fra-2\/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production. J Cell Biol. 2010;190(6):1093\u2013106.","journal-title":"J Cell Biol"},{"issue":"14","key":"417_CR6","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1038\/sj.emboj.7600282","volume":"23","author":"R Eferl","year":"2004","unstructured":"Eferl R, Hoebertz A, Schilling AF, Rath M, Karreth F, Kenner L, et al. The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J. 2004;23(14):2789\u201399.","journal-title":"EMBO J"},{"issue":"3","key":"417_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1083\/jcb.122.3.685","volume":"122","author":"AE Grigoriadis","year":"1993","unstructured":"Grigoriadis AE, Schellander K, Wang ZQ, Wagner EF. Osteoblasts are target cells for transformation in c-fos Transgenic mice. J Cell Biol. 1993;122(3):685\u2013701.","journal-title":"J Cell Biol"},{"issue":"2","key":"417_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1128\/jvi.44.2.674-682.1982","volume":"44","author":"T Curran","year":"1982","unstructured":"Curran T, Peters G, Van Beveren C, Teich NM, Verma IM. FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA. J Virol. 1982;44(2):674\u201382.","journal-title":"J Virol"},{"issue":"6","key":"417_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1159\/000011912","volume":"55","author":"G Gamberi","year":"1998","unstructured":"Gamberi G, Benassi MS, Bohling T, Ragazzini P, Molendini L, Sollazzo MR, et al. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology. 1998;55(6):556\u201363.","journal-title":"Oncology"},{"issue":"7","key":"417_CR10","first-page":"989","volume":"5","author":"JX Wu","year":"1990","unstructured":"Wu JX, Carpenter PM, Gresens C, Keh R, Niman H, Morris JW, et al. The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene. 1990;5(7):989\u20131000.","journal-title":"Oncogene"},{"issue":"11","key":"417_CR11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","volume":"14","author":"JM Argiles","year":"2014","unstructured":"Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: Understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754\u201362.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"417_CR12","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1111\/j.1460-9568.2005.04102.x","volume":"21","author":"JP Konsman","year":"2005","unstructured":"Konsman JP, Blomqvist A. Forebrain patterns of c-Fos and FosB induction during cancer-associated anorexia-cachexia in rat. Eur J Neurosci. 2005;21(10):2752\u201366.","journal-title":"Eur J Neurosci"},{"issue":"1","key":"417_CR13","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1038\/s41467-024-48971-1","volume":"15","author":"Q Sun","year":"2024","unstructured":"Sun Q, van de Lisdonk D, Ferrer M, Gegenhuber B, Wu M, Park Y, et al. Area Postrema neurons mediate interleukin-6 function in cancer cachexia. Nat Commun. 2024;15(1):4682.","journal-title":"Nat Commun"},{"key":"417_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1186\/1471-2407-14-997","volume":"14","author":"SM Judge","year":"2014","unstructured":"Judge SM, Wu CL, Beharry AW, Roberts BM, Ferreira LF, Kandarian SC, et al. Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia. BMC Cancer. 2014;14:997.","journal-title":"BMC Cancer"},{"issue":"5","key":"417_CR15","first-page":"1239","volume":"30","author":"R Moore-Carrasco","year":"2007","unstructured":"Moore-Carrasco R, Busquets S, Almendro V, Palanki M, Lopez-Soriano FJ, Argiles JM. The AP-1\/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. Int J Oncol. 2007;30(5):1239\u201345.","journal-title":"Int J Oncol"},{"issue":"1","key":"417_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13395-022-00303-x","volume":"12","author":"AR Barutcu","year":"2022","unstructured":"Barutcu AR, Elizalde G, Gonzalez AE, Soni K, Rinn JL, Wagers AJ, et al. Prolonged FOS activity disrupts a global myogenic transcriptional program by altering 3D chromatin architecture in primary muscle progenitor cells. Skelet Muscle. 2022;12(1):20.","journal-title":"Skelet Muscle"},{"issue":"2","key":"417_CR17","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.febslet.2005.12.084","volume":"580","author":"R Moore-Carrasco","year":"2006","unstructured":"Moore-Carrasco R, Garcia-Martinez C, Busquets S, Ametller E, Barreiro E, Lopez-Soriano FJ, et al. The AP-1\/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia. FEBS Lett. 2006;580(2):691\u20136.","journal-title":"FEBS Lett"},{"issue":"1","key":"417_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41420-020-00395-8","volume":"7","author":"S Zhu","year":"2021","unstructured":"Zhu S, Yang N, Guan Y, Wang X, Zang G, Lv X, et al. GDF15 promotes glioma stem cell-like phenotype via regulation of ERK1\/2-c-Fos-LIF signaling. Cell Death Discov. 2021;7(1):3.","journal-title":"Cell Death Discov"},{"key":"417_CR19","doi-asserted-by":"crossref","unstructured":"Jagodzinska A, Chudecka-Glaz A, Michalczyk K, Pius-Sadowska E, Wieder-Huszla S, Jurczak A, et al. The diagnostic role of FGF 21 in endometrial cancer and other pathologies of the uterine corpus. Diagnostics (Basel). 2023;13(3).","DOI":"10.3390\/diagnostics13030399"},{"key":"417_CR20","doi-asserted-by":"crossref","unstructured":"Kang YE, Kim JT, Lim MA, Oh C, Liu L, Jung SN, et al. Association between circulating fibroblast growth factor 21 and aggressiveness in thyroid cancer. Cancers (Basel). 2019;11(8).","DOI":"10.3390\/cancers11081154"},{"key":"417_CR21","doi-asserted-by":"crossref","unstructured":"Knott ME, Minatta JN, Roulet L, Gueglio G, Pasik L, Ranuncolo SM, et al. Circulating fibroblast growth factor 21 (Fgf21) as diagnostic and prognostic biomarker in renal cancer. J Mol Biomark Diagn. 2016;1(2).","DOI":"10.4172\/2155-9929.S2-015"},{"issue":"4","key":"417_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41419-021-03588-w","volume":"12","author":"H Dai","year":"2021","unstructured":"Dai H, Hu W, Zhang L, Jiang F, Mao X, Yang G, et al. FGF21 facilitates autophagy in prostate cancer cells by inhibiting the PI3K-Akt-mTOR signaling pathway. Cell Death Dis. 2021;12(4):303.","journal-title":"Cell Death Dis"},{"issue":"5","key":"417_CR23","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1053\/j.gastro.2019.07.030","volume":"157","author":"Y Luo","year":"2019","unstructured":"Luo Y, Yang Y, Liu M, Wang D, Wang F, Bi Y, et al. Oncogenic KRAS reduces expression of FGF21 in acinar cells to promote pancreatic tumorigenesis in mice on a High-Fat diet. Gastroenterology. 2019;157(5):1413\u2013e2811.","journal-title":"Gastroenterology"},{"issue":"12","key":"417_CR24","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/mc.20241","volume":"45","author":"X Huang","year":"2006","unstructured":"Huang X, Yu C, Jin C, Yang C, Xie R, Cao D, et al. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog. 2006;45(12):934\u201342.","journal-title":"Mol Carcinog"},{"key":"417_CR25","doi-asserted-by":"publisher","first-page":"118875","DOI":"10.1016\/j.lfs.2020.118875","volume":"269","author":"X Yu","year":"2021","unstructured":"Yu X, Li Y, Jiang G, Fang J, You Z, Shao G, et al. FGF21 promotes non-small cell lung cancer progression by SIRT1\/PI3K\/AKT signaling. Life Sci. 2021;269:118875.","journal-title":"Life Sci"},{"issue":"5","key":"417_CR26","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.cmet.2024.03.013","volume":"36","author":"C Hu","year":"2024","unstructured":"Hu C, Qiao W, Li X, Ning ZK, Liu J, Dalangood S, et al. Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8(+)T cells. Cell Metab. 2024;36(5):1168.","journal-title":"Cell Metab"},{"issue":"9","key":"417_CR27","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1210\/en.2013-1191","volume":"154","author":"JP Camporez","year":"2013","unstructured":"Camporez JP, Jornayvaz FR, Petersen MC, Pesta D, Guigni BA, Serr J, et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology. 2013;154(9):3099\u2013109.","journal-title":"Endocrinology"},{"issue":"11","key":"417_CR28","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1210\/en.2009-0532","volume":"150","author":"MK Badman","year":"2009","unstructured":"Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology. 2009;150(11):4931\u201340.","journal-title":"Endocrinology"},{"issue":"6","key":"417_CR29","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627\u201335.","journal-title":"J Clin Invest"},{"issue":"7","key":"417_CR30","first-page":"861","volume":"4","author":"U Ruther","year":"1989","unstructured":"Ruther U, Komitowski D, Schubert FR, Wagner EF. c-fos expression induces bone tumors in Transgenic mice. Oncogene. 1989;4(7):861\u20135.","journal-title":"Oncogene"},{"issue":"3","key":"417_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0092-8674(04)00344-7","volume":"117","author":"X Yang","year":"2004","unstructured":"Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry syndrome. Cell. 2004;117(3):387\u201398.","journal-title":"Cell"},{"issue":"3","key":"417_CR32","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1172\/JCI200522877","volume":"115","author":"JP David","year":"2005","unstructured":"David JP, Mehic D, Bakiri L, Schilling AF, Mandic V, Priemel M, et al. Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J Clin Invest. 2005;115(3):664\u201372.","journal-title":"J Clin Invest"},{"key":"417_CR33","doi-asserted-by":"crossref","unstructured":"David JP, Neff L, Chen Y, Rincon M, Horne WC, Baron R. A new method to isolate large numbers of rabbit osteoclasts and osteoclast-like cells: application to the characterization of serum response element binding proteins during osteoclast differentiation. J Bone Miner Res. 1998;13:1730\u20138.","DOI":"10.1359\/jbmr.1998.13.11.1730"},{"key":"417_CR34","doi-asserted-by":"crossref","unstructured":"David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci. 2002;115:4317\u201325.","DOI":"10.1242\/jcs.00082"},{"issue":"1","key":"417_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/art.39425","volume":"68","author":"K Schwabe","year":"2016","unstructured":"Schwabe K, Garcia M, Ubieta K, Hannemann N, Herbort B, Luther J, et al. Inhibition of osteoarthritis by Adipose-Derived stromal cells overexpressing Fra-1 in mice. Arthritis Rheumatol. 2016;68(1):138\u201351.","journal-title":"Arthritis Rheumatol"},{"issue":"Pt 9","key":"417_CR36","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1242\/jcs.079855","volume":"124","author":"J Luther","year":"2011","unstructured":"Luther J, Driessler F, Megges M, Hess A, Herbort B, Mandic V, et al. Elevated Fra-1 expression causes severe lipodystrophy. J Cell Sci. 2011;124(Pt 9):1465\u201376.","journal-title":"J Cell Sci"},{"issue":"2","key":"417_CR37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/72855","volume":"24","author":"K Matsuo","year":"2000","unstructured":"Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet. 2000;24(2):184\u20137.","journal-title":"Nat Genet"},{"key":"417_CR38","doi-asserted-by":"publisher","first-page":"6737345","DOI":"10.1155\/2016\/6737345","volume":"2016","author":"R Dai","year":"2016","unstructured":"Dai R, Wang Z, Samanipour R, Koo KI, Kim K. Adipose-Derived stem cells for tissue engineering and regenerative medicine applications. Stem Cells Int. 2016;2016:6737345.","journal-title":"Stem Cells Int"},{"key":"417_CR39","doi-asserted-by":"crossref","unstructured":"Franz K, Ost M, Otten L, Herpich C, Coleman V, Endres AS, et al. Higher serum levels of fibroblast growth factor 21 in old patients with cachexia. Nutrition. 2019;63\u20134:81\u20136.","DOI":"10.1016\/j.nut.2018.11.004"},{"issue":"5","key":"417_CR40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395.","journal-title":"Lancet Oncol"},{"key":"417_CR41","doi-asserted-by":"crossref","unstructured":"Larson KR, Jayakrishnan D, Soto Sauza KA, Goodson ML, Chaffin AT, Davidyan A, et al. FGF21 induces skeletal muscle atrophy and increases amino acids in female mice: A potential role for glucocorticoids. Endocrinology. 2024;165(3).","DOI":"10.1210\/endocr\/bqae004"},{"issue":"3","key":"417_CR42","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/jcsm.12409","volume":"10","author":"LJ Oost","year":"2019","unstructured":"Oost LJ, Kustermann M, Armani A, Blaauw B, Romanello V. Fibroblast growth factor 21 controls mitophagy and muscle mass. J Cachexia Sarcopenia Muscle. 2019;10(3):630\u201342.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"26","key":"417_CR43","doi-asserted-by":"publisher","first-page":"10853","DOI":"10.1073\/pnas.0904187106","volume":"106","author":"MJ Potthoff","year":"2009","unstructured":"Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A. 2009;106(26):10853\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"417_CR44","first-page":"819","volume":"66","author":"GG Eskiler","year":"2019","unstructured":"Eskiler GG, Bezdegumeli E, Ozman Z, Ozkan AD, Bilir C, Kucukakca BN, et al. IL-6 mediated JAK\/STAT3 signaling pathway in cancer patients with cachexia. Bratisl Lek Listy. 2019;66(11):819\u201326.","journal-title":"Bratisl Lek Listy"},{"issue":"4","key":"417_CR45","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/cvr\/cvn336","volume":"81","author":"T Peng","year":"2009","unstructured":"Peng T, Zhang T, Lu X, Feng Q. JNK1\/c-fos inhibits cardiomyocyte TNF-alpha expression via a negative crosstalk with ERK and p38 MAPK in endotoxaemia. Cardiovasc Res. 2009;81(4):733\u201341.","journal-title":"Cardiovasc Res"},{"issue":"7","key":"417_CR46","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1210\/en.2010-1477","volume":"152","author":"M Pinent","year":"2011","unstructured":"Pinent M, Prokesch A, Hackl H, Voshol PJ, Klatzer A, Walenta E, et al. Adipose triglyceride lipase and hormone-sensitive lipase are involved in fat loss in JunB-deficient mice. Endocrinology. 2011;152(7):2678\u201389.","journal-title":"Endocrinology"},{"issue":"4","key":"417_CR47","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/cdd.2013.198","volume":"21","author":"J Luther","year":"2014","unstructured":"Luther J, Ubieta K, Hannemann N, Jimenez M, Garcia M, Zech C, et al. Fra-2\/AP-1 controls adipocyte differentiation and survival by regulating PPARgamma and hypoxia. Cell Death Differ. 2014;21(4):655\u201364.","journal-title":"Cell Death Differ"},{"issue":"7","key":"417_CR48","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1128\/MCB.24.7.2820-2830.2004","volume":"24","author":"M Kveiborg","year":"2004","unstructured":"Kveiborg M, Sabatakos G, Chiusaroli R, Wu M, Philbrick WM, Horne WC, et al. DeltaFosB induces osteosclerosis and decreases adipogenesis by two independent cell-autonomous mechanisms. Mol Cell Biol. 2004;24(7):2820\u201330.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"417_CR49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1210\/en.2008-0678","volume":"150","author":"GC Rowe","year":"2009","unstructured":"Rowe GC, Choi CS, Neff L, Horne WC, Shulman GI, Baron R. Increased energy expenditure and insulin sensitivity in the high bone mass DeltaFosB Transgenic mice. Endocrinology. 2009;150(1):135\u201343.","journal-title":"Endocrinology"},{"issue":"2","key":"417_CR50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0165-4608(98)00024-7","volume":"105","author":"U Ruther","year":"1998","unstructured":"Ruther U. Induction of bone tumors in Transgenic mice by C-FOS depends on the presence of a retroviral long terminal repeat. Cancer Genet Cytogenet. 1998;105(2):123\u20137.","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"417_CR51","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cmet.2013.11.018","volume":"19","author":"SC Hasenfuss","year":"2014","unstructured":"Hasenfuss SC, Bakiri L, Thomsen MK, Williams EG, Auwerx J, Wagner EF. Regulation of steatohepatitis and PPARgamma signaling by distinct AP-1 dimers. Cell Metab. 2014;19(1):84\u201395.","journal-title":"Cell Metab"},{"issue":"2","key":"417_CR52","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1124\/mol.108.044826","volume":"74","author":"ES Muise","year":"2008","unstructured":"Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, Yuan X, et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic States. Mol Pharmacol. 2008;74(2):403\u201312.","journal-title":"Mol Pharmacol"},{"issue":"6","key":"417_CR53","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","volume":"5","author":"T Inagaki","year":"2007","unstructured":"Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5(6):415\u201325.","journal-title":"Cell Metab"},{"key":"417_CR54","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.molmet.2018.12.003","volume":"20","author":"F Xiao","year":"2019","unstructured":"Xiao F, Guo Y, Deng J, Yuan F, Xiao Y, Hui L, et al. Hepatic c-Jun regulates glucose metabolism via FGF21 and modulates body temperature through the neural signals. Mol Metab. 2019;20:138\u201348.","journal-title":"Mol Metab"},{"key":"417_CR55","doi-asserted-by":"publisher","first-page":"114823","DOI":"10.1016\/j.bcp.2021.114823","volume":"194","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Le Y, Ji Y, Yarde S, Yu X, Cheng X. Activation of activator protein-1-fibroblast growth factor 21 signaling attenuates cisplatin hepatotoxicity. Biochem Pharmacol. 2021;194:114823.","journal-title":"Biochem Pharmacol"},{"issue":"24","key":"417_CR56","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.21037\/atm-20-7269","volume":"8","author":"Z Huang","year":"2020","unstructured":"Huang Z, Zhong L, Zhu J, Xu H, Ma W, Zhang L, et al. Inhibition of IL-6\/JAK\/STAT3 pathway rescues denervation-induced skeletal muscle atrophy. Ann Transl Med. 2020;8(24):1681.","journal-title":"Ann Transl Med"},{"issue":"3","key":"417_CR57","doi-asserted-by":"publisher","first-page":"E410","DOI":"10.1152\/ajpendo.00039.2012","volume":"303","author":"A Bonetto","year":"2012","unstructured":"Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, et al. JAK\/STAT3 pathway Inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab. 2012;303(3):E410\u201321.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"417_CR58","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/rco2.24","volume":"3","author":"G Arora","year":"2020","unstructured":"Arora G, Gupta A, Guo T, Gandhi A, Laine A, Williams D, et al. JAK inhibitors suppress cancer Cachexia-Associated anorexia and adipose wasting in mice. JCSM Rapid Commun. 2020;3(2):115\u201328.","journal-title":"JCSM Rapid Commun"},{"issue":"3","key":"417_CR59","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.cmet.2014.06.010","volume":"20","author":"S Vernia","year":"2014","unstructured":"Vernia S, Cavanagh-Kyros J, Garcia-Haro L, Sabio G, Barrett T, Jung DY, et al. The PPARalpha-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway. Cell Metab. 2014;20(3):512\u201325.","journal-title":"Cell Metab"},{"key":"417_CR60","doi-asserted-by":"crossref","unstructured":"Kang SG, Lee SE, Choi MJ, Chang JY, Kim JT, Zhang BY, et al. Th2 cytokines increase the expression of fibroblast growth factor 21 in the liver. Cells. 2021;10(6).","DOI":"10.3390\/cells10061298"},{"issue":"1","key":"417_CR61","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s42255-023-00945-1","volume":"6","author":"X Zhang","year":"2024","unstructured":"Zhang X, Ding X, Wang C, Le Q, Wu D, Song A, et al. Depletion of JunB increases adipocyte thermogenic capacity and ameliorates diet-induced insulin resistance. Nat Metab. 2024;6(1):78\u201393.","journal-title":"Nat Metab"},{"issue":"1","key":"417_CR62","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10753-023-01905-3","volume":"47","author":"M Cai","year":"2024","unstructured":"Cai M, Ye H, Zhu X, Li X, Cai L, Jin J, et al. Fibroblast growth factor 21 relieves Lipopolysaccharide-Induced acute lung injury by suppressing JAK2\/STAT3 signaling pathway. Inflammation. 2024;47(1):209\u201326.","journal-title":"Inflammation"},{"issue":"12B","key":"417_CR63","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1101\/gad.2.12b.1687","volume":"2","author":"FJ Rauscher","year":"1988","unstructured":"Rauscher FJ 3rd, Voulalas PJ, Franza BR Jr., Curran T. Fos and Jun bind cooperatively to the AP-1 site: reconstitution in vitro. Genes Dev. 1988;2(12B):1687\u201399.","journal-title":"Genes Dev"},{"issue":"13","key":"417_CR64","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1128\/MCB.22.13.4952-4964.2002","volume":"22","author":"L Bakiri","year":"2002","unstructured":"Bakiri L, Matsuo K, Wisniewska M, Wagner EF, Yaniv M. Promoter specificity and biological activity of tethered AP-1 dimers. Mol Cell Biol. 2002;22(13):4952\u201364.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"417_CR65","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1101\/gad.276733.115","volume":"30","author":"M Petruzzelli","year":"2016","unstructured":"Petruzzelli M, Wagner EF. Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes Dev. 2016;30(5):489\u2013501.","journal-title":"Genes Dev"},{"key":"417_CR66","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fendo.2013.00194","volume":"4","author":"Y Luo","year":"2013","unstructured":"Luo Y, McKeehan WL. Stressed liver and muscle call on adipocytes with FGF21. Front Endocrinol (Lausanne). 2013;4:194.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"417_CR67","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.clnu.2017.06.017","volume":"36","author":"J Arends","year":"2017","unstructured":"Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017;36(5):1187\u201396.","journal-title":"Clin Nutr"},{"issue":"2","key":"417_CR68","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/jcsm.12391","volume":"10","author":"IMG da Rocha","year":"2019","unstructured":"da Rocha IMG, Marcadenti A, de Medeiros GOC, Bezerra RA, Rego JFM, Gonzalez MC, et al. Is cachexia associated with chemotherapy toxicities in Gastrointestinal cancer patients? A prospective study. J Cachexia Sarcopenia Muscle. 2019;10(2):445\u201354.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"417_CR69","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s10147-024-02467-6","volume":"29","author":"J Furuse","year":"2024","unstructured":"Furuse J, Osugi F, Machii K, Niibe K, Endo T. Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan. Int J Clin Oncol. 2024;29(4):456\u201363.","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"417_CR70","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","volume":"13","author":"CM Prado","year":"2007","unstructured":"Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13(11):3264\u20138.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"417_CR71","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.20.00611","volume":"38","author":"EJ Roeland","year":"2020","unstructured":"Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol. 2020;38(21):2438\u201353.","journal-title":"J Clin Oncol"},{"issue":"5","key":"417_CR72","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/ehf2.12502","volume":"6","author":"M Refsgaard Holm","year":"2019","unstructured":"Refsgaard Holm M, Christensen H, Rasmussen J, Johansen ML, Schou M, Faber J, et al. Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation. ESC Heart Fail. 2019;6(5):983\u201391.","journal-title":"ESC Heart Fail"},{"issue":"5","key":"417_CR73","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/gerona\/gly153","volume":"74","author":"M Conte","year":"2019","unstructured":"Conte M, Ostan R, Fabbri C, Santoro A, Guidarelli G, Vitale G, et al. Human aging and longevity are characterized by high levels of mitokines. J Gerontol Biol Sci Med Sci. 2019;74(5):600\u20137.","journal-title":"J Gerontol Biol Sci Med Sci"},{"key":"417_CR74","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.canlet.2020.11.026","volume":"499","author":"W Lu","year":"2021","unstructured":"Lu W, Li X, Luo Y. FGF21 in obesity and cancer: new insights. Cancer Lett. 2021;499:5\u201313.","journal-title":"Cancer Lett"}],"container-title":["Cancer &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40170-025-00417-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-025-00417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-025-00417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:03:20Z","timestamp":1781651000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40170-025-00417-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1186\/s40170-025-00417-y","relation":{},"ISSN":["2049-3002"],"issn-type":[{"value":"2049-3002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the local animal facility and by the \u2018Amt f\u00fcr Gesundheit und Verbraucherschutz\u2019 (Org_633, Org_984, N22\/059, G16\/073).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}